Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Glatiramer acetate biases dendritic cells towards an anti-inflammatory phenotype by modulating OPN, IL-17, and RORγt responses and by increasing IL-10 production in experimental allergic encephalomyelitis.
Chemotactic Cytokines: Gordon Research Conference on Molecular and Cellular Mechanisms in Health and Disease
Acute transverse myelitis: demyelinating, inflammatory, and infectious myelopathies.
Disease-modifying drugs reduce cortical lesion accumulation and atrophy progression in relapsing-remitting multiple sclerosis: results from a 48-month extension study.
Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.
Mitoxantrone and ametantrone induce interstrand cross-links in DNA of tumour cells.
Rituximab and multiple sclerosis.
Biogen Idec and Abbott Announce Enrollment of First Patient in Global Phase III Study of Daclizumab for Relapse-Remitting Multiple Sclerosis
Immunosuppressive properties of mesenchymal stem cells: advances and applications.
Forward Pharma Receives Decision to Grant From EPO for DMF Patent in Europe
The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.
Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy.
American Society for Cell Biology Annual Meeting
Characterization of CD56bright NK cells in daclizumab HYP-treated RRMS patients
Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.
Amyloid fibrils activate B-1a lymphocytes to ameliorate inflammatory brain disease.
Cladribine exerts an immunomodulatory effect on human and murine dendritic cells.
Cladribine interferes with IL-1β synaptic effects in experimental multiple sclerosis.
Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre.
Evaluation of pattern-reversal visual evoked potential in patients with neuromyelitis optica.
Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.
Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.
Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration.
Alemtuzumab benefits hard-to-treat MS patients

Pages